retatrutide new england journal of medicine 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Phase 2 Trial of Retatrutide

Many studies report that matrix-related markers move in directions associated with remodeling activity

Some researchers have suggested that rates of eye strokes (NAION) and other vision-related complications might be higher among people taking Zepbound and other GLP-1s

The occurrence of vomiting not only brings physical discomfort to patients, but may also lead to serious consequences such as electrolyte imbalance and dehydration

Clinical Trial Evidence: Landmark cardiovascular outcome trials (CVOTs) like the SELECT trial (for semaglutide) have shown a significant reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death

It checks a box but doesn't move the needle

In individuals without diabetes, the potential for hypoglycemia with GLP-1RA treatment would therefore also be expected to be low